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Wnt-5a is one of the most highly investigated non-canonical Wnts and has been implicated in almost all aspects of non-canonical
Wnt signalling. In terms of cancer development, Wnt-5a has, until recently, lived in the shadow of its better-characterised relatives.
This was largely because of its apparent inability to transform cells or signal through the canonical b-catenin pathway that is so
important in cancer, particularly colorectal cancer. Recent work in a wide range of human tumours has pointed to a critical role for
Wnt-5a in malignant progression, but there is conflicting evidence whether Wnt-5a has a tumour-promoting or -suppressing role.
Emerging evidence suggests that the functions of Wnt-5a can be drastically altered depending on the availability of key receptors.
Hence, the presence or absence of these receptors may go some way to explain the conflicting role of Wnt-5a in different cancers.
This review summarises our current understanding of Wnt-5a and cancer.
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Wnt-5a is 1 of 19 Wnt proteins that make up the family of secreted
lipid-modified glycoproteins that show a highly regulated pattern
of expression and has distinct roles during development and
tissue homoeostasis. The importance of Wnt-5a in multiple
developmental pathways is illustrated by the phenotype of
Wnt-5a
 /  mice, which die at birth and show many defective
features such as truncated bodies, facial abnormalities and short
deformed limbs (Oishi et al, 2003). Wnts have been implicated in
oncogenesis as early studies showed that Wnt-1 was overexpressed
in mammary epithelial adenocarcinomas as a result of integration
of the mouse mammary tumour virus. Since then, deregulated
expression of Wnts and Wnt signalling has been linked to multiple
forms of epithelial cancer (Giles et al, 2003). However, on account
of the inability of Wnt-5a to transform cells, its role in cancer
promotion was not immediately apparent. Nevertheless, recent
work has pointed to a critical role of Wnt-5a in malignant
progression (Jonsson et al, 2002; Huang et al, 2005; Roman-Gomez
et al, 2007; Da Forno et al, 2008), but whether it is afforded by a
tumour-suppressing effect or an oncogenic effect is questionable.
The fact that Wnt-5a has been described as both challenges the
simplistic classification of genes as tumour promoters or
suppressors. In this review, we discuss the opposing roles of
Wnt-5a in cancer development and show that an account of the
Wnt-5a cellular and signalling context should be taken before a
functional classification can be made.
WNT SIGNALLING PATHWAYS
The Wnt signalling pathways are usually activated through binding
of the secreted Wnt molecules to the conserved C-terminal
cytosolic domain of a family of nine large multipass transmem-
brane receptors called the Frizzled receptor proteins (Fz).
However, Wnts do not signal exclusively through these receptors
as others, such as the ROR2 receptor, have been identified (Oishi
et al, 2003). The interaction between individual Wnts and their
specific receptors is thought to dictate the type of downstream
signalling pathways that are activated. Accordingly, the Wnts have
historically been divided into two classes: those that signal through
the ‘canonical’ or the ‘non-canonical’ signalling pathway.
The canonical signalling pathway performs a variety of different
functions throughout development. Canonical Wnts are thought to
activate a signal-transduction pathway that induces the nuclear
accumulation and transcriptional activation of b-catenin (Giles
et al, 2003). A process that can cause duplication of the embryonic
axis in Xenopus (x) (xWnt-1, xWnt-3a, xWnt-8a and xWnt-8b)
(Du et al, 1995) and transform mouse (m) mammary epithelial
cells (mWnt-1, mWnt-2, mWnt-3, mWnt-3a) (Shimizu et al, 1997),
this pathway is essential for the development of dorsal polarity
during grastulation (Brannon et al, 1997). In addition to a role in
normal development, deregulation has been shown to be
integral to cancer development and progression by, among
other functions, promoting cancer cell proliferation and migration
(Giles et al, 2003).
The non-canonical signalling pathway is essentially an umbrella
term for all Wnt-activated cellular signalling pathways that do not
promote b-catenin-mediated transcription, and numerous path-
ways have been identified. In contrast to the canonical Wnts, the
non-canonical Wnts do not signal through b-catenin, do not cause
duplication of the embryonic axis in Xenopus (xWnt-4, xWnt-5A
and xWnt-11) (Du et al, 1995) and are unable to transform mouse
mammary epithelial cells (mWnt-4, mWnt-5a, mWnt-5b, mWnt-6
and mWnt-7b) (Shimizu et al, 1997). Furthermore, it is well
established that non-canonical Wnts can antagonise the functions
of canonical Wnts (Torres et al, 1996). A recent study provided
further evidence of the opposing roles of different Wnts as
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in many processes (Veeman et al, 2003; Semenov et al, 2007),
non-canonical Wnts are generally considered to control
morphogenic movements. The most well-recognised categories
of non-canonical signalling are the planar cell polarity pathway
(PCP) and the Wnt calcium signalling pathway. Wnt-5a is one of
the most highly investigated non-canonical Wnts, and has been
shown to be involved in almost all aspects of non-canonical Wnt
signalling.
Interestingly, the convention of two independent Wnt pathways
has remained for some time, but emerging evidence suggests that
the pathways are not as autonomous as originally thought. For
instance, although Wnt-5a is thought to primarily function though
the non-canonical pathway, it can, under certain circumstances,
signal through the canonical pathway. The possibility of interac-
tion between these two pathways may explain in part the
uncertainties of the role of Wnt-5a in cancer.
THE ROLE OF WNT-5A IN WNT SIGNALLING AND
IMPLICATIONS FOR CANCER
The non-canonical pathway, PCP, was identified in Drosophila,
and is essential for organising the orientation of cells in tissues. In
Drosophila, PCP is a complex process involving the spatial
organisation of multiple signalling molecules (Jones and Chen,
2007). Signalling results in the activation of a number of
cytoskeleton regulators including DAAM1, Rac, Rho and Rho
kinase (Jones and Chen, 2007). Although this pathway was
identified in Drosophila, it is by no means confined to this
organism and has also been identified in vertebrates (Green and
Davidson, 2007), but the extent of the similarities are unknown
(Mlodzik, 2002). Furthermore, vertebrates use PCP to allow cells to
undergo convergence and extension movements during organo-
genesis (Wallingford et al, 2002). As a result, PCP is now thought
to be essential for the organisation, orientation and morphogenic
movements of multiple invertebrate and vertebrate epithelial and
mesenchymal cells throughout normal development and is thought
to be activated in cancer (Jones and Chen, 2007). Wnt-5a was
recently shown to be essential for controlling PCP in vertebrates
(Qian et al, 2007) (Figure 1A). In addition, Wnt-5a, in the presence
of a CXCL12 chemokine gradient, was able to polarise the cellular
cytoskeleton of WM239a melanoma cells through a process
dependent on dishevelled (DSH), RhoB and Rab4 to promote
cellular migration towards the source of the chemokine (Witze
et al, 2008). Although these reports shed some light on the role of
Wnt-5a in PCP, the downstream signalling pathways activated to
bring about its effects are still enigmatic, but it is clear that it
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Figure 1 An overview of Wnt-5a signalling. (A) Wnt-5a can activate PCP through a process dependent on Roh A and possibly Roh B leading to the
control of cellular movement. (B) Wnt-5a uses numerous signalling molecules leading to the release of Ca
2þ resulting in various cellular effects including cell
movement and inhibition of the canonical Wnt signalling pathway. (C) Wnt-5a can bind the ROR-2 receptor activating JNK and the cytoskeleton as well as
inhibiting b-catenin/TCF dependent transcription. (D) Wnt-5a can inhibit b-catenin/TCF-dependent transcription through Shia-1. (E) In the presence
of FZ4 and LRP-5, Wnt-5a can activate b-catenin/TCF-dependent transcription. (F) Wnt-5a can activate PKA, which in turn can inhibit GSK-b to promote
b-catenin/TCF-dependent transcription. Figure adapted from Semenov et al (2007).
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movement. This ability of Wnt-5a to promote cell movement has
crucial implications for cancer progression.
The second main Wnt-5a-dependent pathway is the calcium-
dependent signalling pathway. Here, the non-canonical Wnts can
trigger intracellular calcium flux, which can lead to the activation
of calcium-dependent signalling molecules such as calmodulin-
dependent protein Kinase II (CAMKII) and protein kinase C (PKC)
(Kuhl et al, 2000b). The pathways activated downstream perform
many different tasks, and there is a degree of crossover between
the calcium-dependent pathway and the PCP pathway. In contrast
with the canonical pathway, this pathway can control the fate of
ventral cells in Xenopus (Kuhl et al, 2000a). Some of the earliest
experiments carried out in Xenopus embryos showed that
Xenopus Wnt-5A (Xwnt-5A) was able to activate Rat (r) FZ-2,
resulting in intracellular Ca
2þ release (Slusarski et al, 1997b). The
components of the signalling pathway upstream of the release of
Ca
2þ are still debated, but it is clear that a number of signalling
molecules such as DSH (Sheldahl et al, 2003) and p38 (Ma and
Wang, 2007) are activated as is G-protein-linked phosphatidyli-
nositol signalling (Slusarski et al, 1997a). The Ca
2þ release is
thought to lead to activation of CamKII ensuring correct axis
formation and the promotion of ventral cell fate (Kuhl et al,
2000a). Studies have also shown that XWnt-5A can bind to rFZ-2
to activate PKC (Sheldahl et al, 2003) (Figure 1B). CamKII and
PKC activation by Wnt-5a is maintained in higher organisms and
is essential for invasion of cancer cells (Weeraratna et al, 2002;
Dissanayake et al, 2007). Therefore, it can be concluded that
overexpression of Wnt-5a could have an oncogenic effect by
stimulating cancer cell invasion.
In addition to Frizzled receptors, Wnt-5a can also bind and
activate the ROR2 tyrosine kinase receptor resulting in the
activation of the actin-binding protein, filamin A, and the JNK
signalling pathway (Oishi et al, 2003; Nomachi et al, 2008)
(Figure 1C). A potential role for these pathways in cancer was
established when Wnt-5a was shown to signal through ROR2 to
induce cellular migration and invasion in murine fibroblast
NIH3T3 cells (Nomachi et al, 2008); if the same occurred in
cancer cells, oncogenic potential could be conferred by Wnt-5a
through the promotion of cancer cell invasion.
In addition to activating non-canonical signalling, Wnt-5a is
also able to inhibit the activation of the canonical signalling
pathway by a number of mechanisms, either by calcium signalling
through CamKII (Torres et al, 1996) or through the ROR2
signalling pathways (Mikels and Nusse, 2006) (Figure 1 B and C).
In turn, these pathways can stimulate the TAK1–NLK pathway to
phosphorylate (Winkel et al, 2008) and inactivate the active b-
catenin transcription complex (Ishitani et al, 2003). Another
proposed mechanism for the inhibition of b-catenin-mediated
transcription is through the upregulation of Sha2, which occurs in
response to Wnt-5a-mediated calcium release in APC mutant cells
(MacLeod et al, 2007) (Figure 1D). In accordance with this, Wnt-5a
has been shown to reduce the activation of b-catenin-mediated
transcription in HCT116 (Ying et al, 2008) and HT-29 colon cancer
cell lines (MacLeod et al, 2007). Through inhibiting the activation
of canonical Wnt signalling, the expression of Wnt-5a is likely to
confer a tumour-suppressive role in tumours that rely on
canonical signalling for survival.
Although the ability of Wnt-5a to inhibit the activation of b-
catenin-mediated transcription is well established, there is
evidence to suggest that in the presence of FZ-4 and LRP-5 and
the absence of ROR2, Wnt-5a can stimulate b-catenin transcrip-
tional activation (Mikels and Nusse, 2006) (Figure 1E). Research
has also shown that Wnt-5a can activate phospho kinase A (PKA)
in primary cultured human dermal fibroblasts, which in turn can
inactivate GSK3-b resulting in stabilisation and nuclear accumula-
tion of b-catenin, and concomitantly promote the activation of an
important cotranscription factor of b-catenin, the CRE-binding
protein (CREB) (Torii et al, 2008) (Figure 1F). Therefore, Wnt-5a,
in the presence of specific FZ isoforms, could promote tumour
growth by activation of the cancer-promoting canonical Wnt
signalling pathway. Nevertheless, it is important to note that this
influence on b-catenin-mediated transcription may only be
effective in some cell types as Wnt-5a was shown to have no
effect on the activation of transcription in MCF-7 breast cancer
cells (Pukrop et al, 2006).
Wnt-5a is one of the most highly investigated non-canonical
Wnts, and has been shown to be involved in almost all aspects of
the non-canonical Wnt signalling pathway. Wnt-5a has ample
opportunity, therefore, to influence cancer development.
EXPRESSION OF WNT-5A IN CANCER
Unsurprisingly, given its functional promiscuity, investigations to
elucidate the role of Wnt-5a in cancer have shown paradoxical
results and studies indicate that it may have a tumour suppressing
or an oncogenic effect depending on the cancer type (Table 1).
A large number of studies have indicated that Wnt-5a commands a
tumour-suppressing effect, and it was shown to be downregulated
in a number of different cancers such as colorectal cancer (Dejmek
et al, 2005a; Ying et al, 2008), neuroblastoma (Blanc et al, 2005),
ductal breast cancer (Jonsson et al, 2002; Dejmek et al, 2005b) and
leukaemias (Liang et al, 2003; Roman-Gomez et al, 2007; Ying et al,
2007). Downregulation of Wnt-5a has been associated with higher
tumour grade (Kremenevskaja et al, 2005; Dejmek et al, 2005a; Liu
et al, 2008) and was shown to be an independent factor indicating
poor prognosis in a number of different tumour subtypes (Jonsson
et al, 2002; Roman-Gomez et al, 2007). These results suggest that
for cancer to progress, Wnt-5a must be actively silenced, a
characteristic feature of tumour suppressors. This tumour-
suppressive role was further evidenced by studies that reintro-
duced Wnt-5a into SW480 colorectal cancer or thyroid cancer
FTC-133 cell lines resulting in decreased invasion, migration,
colonogenicity and proliferation (Kremenevskaja et al, 2005;
Dejmek et al, 2005a). Further evidence of a potential tumour-
suppressive role was shown by a synthetic peptide synthesised to
mimic the biological properties of Wnt-5a. This peptide could
reduce the invasion of breast cancer cell lines in vitro and inhibited
the metastatic spread of 4T1 breast cancer cells from the mammary
fat pad to the lungs and liver by 70–90% in athymic BALB/c mice
(Safholm et al, 2008).
Most studies have involved limited sample sets in terms of
numbers and a significant number have not detailed expression at
both the RNA and protein levels. Studies with much larger sample
sets will provide the necessary statistical power to validate the
extent of the downregulation of Wnt-5a in cancer. However, the
current data do indicate that reduced expression is likely to occur
in over half of each of the tumour types investigated. As the
majority of these studies investigated Wnt-5a protein expression, a
mechanism for this loss of expression has not been established. It
is possible, however, that epigenetic regulation is involved, as
methylation of the Wnt-5a promoter was identified in a large
proportion of lymphoblastic leukaemia patients and in colorectal
cancer patients (Roman-Gomez et al, 2007; Ying et al, 2007, 2008).
The precise mechanisms governing cancer promotion caused by
Wnt-5a downregulation are still unknown. As Wnt-5a can
counteract the effects of canonical Wnt signalling, it seems clear
that its downregulation would be advantageous to cancers driven
by canonical Wnt signalling. However, the mechanisms that inhibit
tumour growth in tumours without active canonical Wnt signalling
remain unclear. It has recently been determined that Wnt-5a can
promote the association of b-catenin and E-cadherin complexes on
the cell membrane leading to increased cellular adhesion (Medrek
et al, 2009). Therefore, reducing Wnt-5a expression may diminish
cellular adhesion through reducing membrane-bound E-cadherin.
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expression has been identified in a large proportion of ductal
breast cancers (Jonsson et al, 2002; Dejmek et al, 2005b), which
rarely have inactivation mutations in E-cadherin (Cleton-Jansen,
2002).
Although there is firm evidence that Wnt-5a has a tumour-
suppressive role, a few studies have pointed to Wnt-5a having an
oncogenic role in tumours arising from a variety of different
tissues (Table 2). Increased expression of Wnt-5a, a hallmark of
oncogenesis, was identified in melanoma skin cancer (Da Forno
et al, 2008), breast cancer cells (Fernandez-Cobo et al, 2007),
gastric cancer (Kurayoshi et al, 2006), pancreatic cancer (Ripka
et al, 2007), non-small-cell lung cancer (Huang et al, 2005) and
prostate cancer (Wang et al, 2007). Increased expression has been
associated with increasing tumour grade (Kurayoshi et al, 2006; Da
Forno et al, 2008), and multivariate analysis showed that
expression was an independent risk factor for reduced metasta-
sis-free and overall survival in patients with melanoma (Da Forno
et al, 2008) or non-small-cell lung cancer (Huang et al, 2005). A
cancer-promoting function was also shown in UACC 1273
melanoma cancer cells (Weeraratna et al, 2002), MKN-74 and
MKN-45 gastric cancer cells (Kurayoshi et al, 2006) and in PANC1,
HT1080, ImimPc1 and MiaPaca pancreatic cancer cell lines (Ripka
et al, 2007), where overexpression of Wnt-5a promoted cell
proliferation and invasion.
The potential role for increased Wnt-5a expression in malignant
melanoma has recently been outlined as a study established that
nuclear b-catenin levels are higher in primary tumours than in
metastases and that low expression of nuclear b-catenin expression
in primary tumours predicts poor survival (Chien et al, 2009). This
suggests that inhibition of canonical Wnt signalling may be
important for progression of malignant melanomas and that the
increased expression of Wnt-5a in high-grade tumours may serve
to inhibit activation of the canonical signalling pathway and
augment cancer growth. Therefore, there is a considerable body of
data that supports the hypothesis that Wnt-5a can advance
particular cancer types, but is unlikely to be a primary or
initiating event.
CONCLUSION
Wnt-5a partakes in many of the Wnt-dependent signalling
processes used during development, tissue homoeostasis and
cancer progression, but its role in the latter is still unclear. Further
large-scale studies may help to clarify the role of Wnt-5a, but as it
has been shown to elicit different downstream effects depending
on receptor availability, these studies are unlikely to achieve
clarification if the expression of Wnt-5a is monitored in isolation.
We feel that the key will be to identify the most important
signalling partners to record. Unfortunately, we do not currently
have a comprehensive understanding of how Wnt-5a brings about
its effects. Indeed, our understanding of the complexities of Wnt
signalling is incomplete (Veeman et al, 2003). Recently, a number
of studies have used siRNA to identify the genes responsible for
controlling canonical Wnt signalling (Major et al, 2008), and
Table 1 Studies where Wnt-5a has tumour-suppressing effect
Tissue type (n)
Detection
method Expression in tumour Disease outcome References
Neuro blastoma (37) mRNA levels Reduced expression in some tumours Reduced expression associated
with poor outcome tumours
Blanc et al (2005)
Colon cancer primary dukes B (55) IH Expression lost or reduced in 50% of tumours Reduced expression strong
predictor of adverse outcome and
low expression correlated with
shorter survival
Dejmek et al
(2005a)
Breast cancer (94) IH Reduced expression in 56% of breast tumours Univariate regression analysis
showed loss of Wnt-5a expression
indicates an increased risk of death
Dejmek et al
(2005b)
Invasive ductal breast carcinomas
(59)
IH Loss of Wnt-5a expression in 44% tumours Loss associated with a higher
histological grade and loss was an
independent predictor of
recurrence
Jonsson et al (2002)
Thyroid cancer
Normal tissue (11)
Papillary (12)
Anaplastic (5)
IH Low expression in normal tissue
High expression in differentiated tumours but
low expression in non differentiated tumours
ND Kremenevskaja et al
(2005)
Acute myeloid leukaemias (AML)
(10) or ALL (10)
mRNA levels Wnt-5a absent in 80% of ALL and at low levels
or absent in all AML
ND Liang et al (2003)
Hepatocellular carcinoma (92) IH Reduction or loss of Wnt-5a protein
expression was found in 81% of tumours
Loss was significantly associated
with higher tumour stage
Liu et al (2008)
Acute lymphoblastic leukaemia
(ALL) cell lines (6) patients (307)
Gene
methylation
Wnt-5a hypermethylation in all cell lines
Hypermethylated in 43% of ALL patients
Hypermethylation lead to reduced Wnt-5a
mRNA expression
Wnt-5a methylation was an
independent prognostic factor
predicting disease-free survival
Roman-Gomez
et al (2007)
Leukaemia Cell lines NL(4),
Leukaemia (4) Burket lymphoma
(6) peripheral blood mononuclear
cells (3)
Lymphoblastoid cell lines (3)
Burket lymphoma tumours (10)
NL tumours (30)
Non–Hodgkin’s lymphomas(36)
Gene
methylation
Wnt-5a highly methylated and mRNA silenced
in all cell lines.
Methylation of Wnt-5a was shown in 50% of
Burket lymphoma, 73% of NL tumours and
31% of Non-Hodgkin’s lymphomas but not in
normal tissue
ND Ying et al (2007)
Colorectal cancer (29)
Normal colon tissues (15)
Gene
methylation
Wnt-5a methylation was detected in 48% of
CRC tumours, but only in 13% of normal tissue
paired normal P¼0.025)
ND Ying et al (2008)
IH¼immunohistochemistry; ND¼no data.
The opposing roles of Wnt-5a in cancer
SL McDonald and A Silver
212
British Journal of Cancer (2009) 101(2), 209–214 & 2009 Cancer Research UKsimilar investigations are likely to be completed soon for non-
canonical Wnt signalling, specifically the role of Wnt-5a. Once an
in-depth understanding of the processes by which Wnt-5a brings
about its cellular effects is achieved, it is likely that its role in
cancer will be clarified.
In addition to its use as a prognostic indicator, the possibility of
Wnt-5a being a target for therapeutics has been raised (Safholm
et al, 2008). One proposed strategy is the use of peptides to mimic
the properties of Wnt-5a (Safholm et al, 2008), although in our
opinion this approach will require considerable caution because of
the wide-ranging roles played by Wnt-5a in the cell. In the cancer
cell, for instance, where Wnt-5a has been silenced, introduction of
a Wnt-5a mimic may concomitantly activate non-canonical
signaling, which also has cancer-promoting properties. Blocking
downstream effectors of Wnt-5a may prove more effective, and
hence the intense level of research into the therapeutic targeting of
Wnt signalling (Ewan and Dale, 2008). With targeting will come a
need to screen patients and their tumours for involvement of Wnt-
5a and its associated signalling partners before chemotherapy to
identify those most likely to benefit. The role of Wnt-5a in cancer
and normal tissue is intriguing and the current intense level of
research will further our understanding and identify novel targets
for therapeutic intervention along with predictive biomarkers for
targeted therapy regimes.
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